论文部分内容阅读
目的观察重组甘精胰岛素联合口服降糖药物治疗2型糖尿病的临床效果。方法选取医院收治的2型糖尿病患者76例为研究对象,随机分为对照组和观察组,每组38例。对照组采用预混人胰岛素30R加格列美脲药物治疗,观察组采用重组甘精胰岛素联合格列美脲治疗,观察2组治疗前后各项指标(空腹血糖、餐后2 h血糖、糖化血红蛋白)、临床疗效及低血糖发生情况。结果治疗后,2组空腹血糖、餐体2 h血糖、糖化血红蛋白数值降低,且观察组各项指标均优于对照组(P<0.05);观察组总有效率为97.3%,高于对照组的84.2%(P<0.05);观察组低血糖发生率为2.6%,低于对照组的13.1%(P<0.05)。结论重组甘精胰岛素联合口服降糖药物治疗2型糖尿病与预混人胰岛素30R联合药物相比可改善患者血糖水平,减少低血糖的发生,提高安全性,值得临床推广应用。
Objective To observe the clinical effect of recombinant glargine and oral hypoglycemic agents on type 2 diabetes mellitus. Methods Totally 76 patients with type 2 diabetes mellitus admitted to hospital were selected as control group and control group, with 38 cases in each group. The control group was treated with insulin 30R plus glibenclamide pretreatment. The observation group was treated with recombinant insulin glargine and glimepiride. The changes of fasting blood glucose, postprandial blood glucose, hemoglobin A1c ), Clinical efficacy and incidence of hypoglycemia. Results After treatment, the values of fasting blood glucose, glycemic hemoglobin and fasting blood glucose in the two groups decreased, and the indexes in the observation group were better than those in the control group (P <0.05). The total effective rate in the observation group was 97.3% (P <0.05). The incidence of hypoglycemia in the observation group was 2.6%, which was lower than that in the control group (13.1%, P <0.05). Conclusion Recombinant glargine combined with oral hypoglycemic agents can improve the blood glucose level, reduce the incidence of hypoglycemia and improve the safety of patients with type 2 diabetes mellitus and pre-mixed insulin 30R combination drugs, which is worthy of clinical application.